Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Update

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) was the target of a large growth in short interest during the month of March. As of March 13th, there was short interest totaling 23,175 shares, a growth of 28.6% from the February 26th total of 18,020 shares. Based on an average trading volume of 120,867 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.0% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on XTNT. BTIG Research reduced their price objective on Xtant Medical from $1.50 to $1.00 and set a “buy” rating on the stock in a research note on Tuesday. Craig Hallum reiterated a “buy” rating on shares of Xtant Medical in a research note on Wednesday, March 18th. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Xtant Medical has an average rating of “Buy” and a consensus price target of $1.00.

Xtant Medical Stock Performance

NYSEAMERICAN XTNT traded up $0.02 during trading hours on Tuesday, reaching $0.56. The company’s stock had a trading volume of 223,974 shares, compared to its average volume of 156,542. The company has a current ratio of 2.21, a quick ratio of 1.06 and a debt-to-equity ratio of 0.35. The business has a 50-day simple moving average of $0.60 and a 200 day simple moving average of $0.67. Xtant Medical has a 52 week low of $0.34 and a 52 week high of $0.95. The stock has a market cap of $78.12 million, a PE ratio of 55.86 and a beta of -0.30.

Institutional Investors Weigh In On Xtant Medical

A number of hedge funds have recently added to or reduced their stakes in XTNT. Jane Street Group LLC acquired a new position in shares of Xtant Medical during the second quarter valued at $26,000. Tradition Wealth Management LLC acquired a new stake in shares of Xtant Medical in the 4th quarter worth about $79,000. Wiregrass Investment Management LLC bought a new stake in Xtant Medical in the 4th quarter valued at about $81,000. Mink Brook Asset Management LLC boosted its stake in Xtant Medical by 125.8% during the 2nd quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after purchasing an additional 60,997 shares during the period. Finally, Nano Cap New Millennium Growth Fund L P acquired a new position in Xtant Medical during the 4th quarter valued at about $220,000. 69.33% of the stock is currently owned by institutional investors.

Key Headlines Impacting Xtant Medical

Here are the key news stories impacting Xtant Medical this week:

• Positive Sentiment: Q4 / FY2025 results showed revenue momentum and profitability: full‑year 2025 revenue was $133.9M (+14% YoY), with positive net income, adjusted EBITDA and operating cash flow; Xtant reported $17.3M cash at year‑end plus $10.5M received after year‑end from a divestiture — supports balance sheet and liquidity. PR Newswire: Financial Results
• Positive Sentiment: Analyst backing: BTIG kept a Buy rating and set a $1.00 price target (down from $1.50), which still implies substantial upside from current levels — provides some analyst conviction for long‑term investors. Benzinga: BTIG Price Target
• Neutral Sentiment: Quarterly highlights and management commentary (earnings call transcript) provide detail on growth drivers, margins and the timing/impact of the divestiture and license revenue roll‑off — useful for modeling 2026 results. Yahoo Finance: Q4 Highlights
• Neutral Sentiment: Full earnings call transcript is available for investors who want verbatim management guidance and Q&A to refine forecasts. Seeking Alpha: Earnings Transcript
• Negative Sentiment: 2026 revenue outlook lowered to $95M–$99M as Companion Spine divestiture and the expiration/roll‑off of Q‑code license revenue reduce near‑term top‑line visibility — this weak guide is the main driver of negative investor reaction. MSN: 2026 Outlook
• Negative Sentiment: Market reaction included an intraday share decline after the weak 2026 outlook was reported; coverage notes the drop in sentiment despite the earnings beat. MSN: Shares Drop
• Negative Sentiment: Short interest has risen materially, which can amplify downside pressure and volatility if negative sentiment persists. American Banking News: Short Interest

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.